Market Place
Sourcing Support
BioVersys Joins EU-Funded RespiriNTM Programme For Drug Development
22 Oct 2024 //
GLOBENEWSWIRE
Bioversys Announces Last Patient Visit In Ph 2 Trial VAB Pneumonia
16 Oct 2024 //
GLOBENEWSWIRE
Nature Reviews Highlights Antibiotic Collaboration Successes
23 Sep 2024 //
GLOBENEWSWIRE
Bioversys Announces GIBF2 Investment, Launches BV100 In China
10 Sep 2024 //
GLOBENEWSWIRE
BioVersys: Non-Dilutive Funding From CF AMR Syndicate Program
04 Jun 2024 //
GLOBENEWSWIRE
BioVersys ink GSK to speed up devep of alpibectir for treatment of tuberculosis
08 May 2024 //
PHARMABIZ
BioVersys Expands GSK Collaboration, Extends Series C By $13.7M
07 May 2024 //
GLOBENEWSWIRE
OpGen Subsidiary Curetis and BioVersys Sign Agreement for Trial Support
25 Oct 2022 //
GLOBENEWSWIRE
BioVersys Gets EIB Funds to Address Antimicrobial Resistance
15 Apr 2021 //
NEUROOTHERS
BioVersys Announces First Subjects Dosed in Phase 1 Clinical Trial of BV100
18 Nov 2020 //
B3C
BioVersys announces first subjects dosed in Ph 1 clinical trial of BV100
18 Nov 2020 //
BIOSPECTRUMASIA
BioVersys Announces CHF 19 Million Financing to Advance AMR Candidates
01 Sep 2020 //
PHARMIWEB
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.